Clinical Trial

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of multiple doses of RO7823653 in participants with DME, administered by intravitreal (IVT) injection as monotherapy and co-administered with faricimab.
Protocol Amendment History 1 change
notable Trial sites expanded: 3 -> 8 locations 2026-04-24
Trial Details
NCT Number NCT07425522
Lead Sponsor Genentech, Inc.
Conditions Diabetic Macular Edema
Enrollment 93 participants
Start Date 2026-04-21
Primary Completion 2028-11-17 (estimated)
Study Completion 2028-11-17 (estimated)
Updated on ClinicalTrials.gov 2026-08-14